NIFS sequenced fetal genome; Wegovy pill OK'd in UK
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NIFS blood test detected 95–99% of genetic variants found by invasive methods in 565 pregnancies at ~17 weeks, sequencing 23,000 genes per fetus across a 2,500+ gene panellink ›
- Dr Christopher Whelan of the Broad Institute will present the test at the European Society for Human Genetics conference in Gothenburg on Saturdaylink ›
- Prof Alexandre Reymond of the University of Lausanne called sequencing an entire fetal genome from maternal blood 'a tour de force' that 'means reproductive medicine will be changed for ever'link ›
- Amniocentesis and CVS carry a roughly 1-in-200 miscarriage risk, a barrier Whelan says NIFS could reduce by giving patients a frontline sequencing tool when ultrasound flags an anomalylink ›
- MHRA approved Novo Nordisk's oral Wegovy semaglutide tablet, making the UK the third country after the US and UAE to authorize it and the first in Europelink ›
- Wegovy tablets start at 1.5mg with monthly escalations to 4mg, 9mg, and 25mg; existing injection users can switch directly to the 25mg tablet if suitablelink ›
- Rep. Erin Houchin (R-Ind.) introduced legislation that would reinstate daily in-person methadone clinic visits and block telehealth prescribing of methadone or buprenorphinelink ›
A non-invasive blood test that sequences the entire fetal genome with 95–99% accuracy cleared a major validation hurdle this week, with researchers at MIT and Harvard's Broad Institute calling it a 'tour de force' that will permanently change reproductive medicine. The NIFS test analyzes small DNA fragments in maternal blood across 2,500+ genes, potentially sparing thousands of women each year the choice between invasive amniocentesis and its 1-in-200 miscarriage risk. In the UK, regulators became the first in Europe to authorize Novo Nordisk's oral Wegovy pill — a daily semaglutide tablet escalated to 25mg — though NICE hasn't priced it for NHS coverage, leaving patients staring at £90–£300 monthly private bills.
The stories behind this week
MHRA approves Wegovy oral weight‑loss pill in UKPatients who struggle with injections now have a daily pill option, potentially lowering out‑of‑pocket costs and increasing adherence, while the NHS awaits NICE’s assessment before covering it. The approval also signals a broader shift toward oral GLP‑1 therapies in Europe.
OIST discovers acetylcholine drives habit change afterUnderstanding acetylcholine's role in breaking habits could lead to targeted treatments for addiction, OCD, and Parkinson’s, where inflexible behavior patterns are core symptoms. This mechanistic insight offers a direct neurochemical target for therapies.
Top five-a-day foods new study says your heart needsMost people eating a standard five-a-day may still lack key heart-protective nutrients, meaning public health guidance could need refinement to specify which produce delivers the greatest benefit, not just how much.
Trump administration pushes back on opioid medsPatients who rely on evidence‑based opioid medications risk losing access as new restrictions could force daily clinic visits, ban telehealth, and encourage early discontinuation, while addiction providers confront policy shifts that contradict clinical guidelines and may raise overdose risk and mortality.
New Blood Test Detects Thousands of Fetal GeneticIf confirmed in wider use, NIFS could spare thousands of women each year from choosing between definitive genetic diagnosis via amniocentesis and its roughly 1-in-200 miscarriage risk — a trade-off the source says drives many to decline invasive testing entirely.
STAT+ Publishes Exclusive Health Tech ArticleSTAT+ subscribers gain immediate access to the exclusive article, while non‑subscribers must subscribe or log in, reinforcing the paywall’s role in controlling who sees the content and limiting broader public exposure.
Steve Brusatte's 'The Story of Birds' Traces EvolutionThe book delivers a rigorous yet readable synthesis of avian evolution, giving general readers and educators a clear picture of birds as living dinosaurs and exposing lesser‑known chapters—Zealandia’s dinosaur‑like fauna and birds’ unusually high neuron counts—that deepen public appreciation of evolutionary science.
Phosphatidylcholine Boost Reverses Mitochondrial AgingThe discovery provides a concrete metabolic target that could help older adults—especially post‑menopausal women—maintain cellular energy and slow age‑related decline, while challenging the prevailing belief that mitochondrial deterioration is irreversible. It suggests that dietary or pharmacologic strategies may meaningfully modify the aging trajectory.
Why it matters: If NIFS holds up in wider use, prenatal care's default reflex — offer a risky invasive test or shrug — collapses into a single blood draw, and tens of thousands of women a year stop choosing between a diagnosis and a miscarriage.
